Recombinant MS4A1 (Ocrelizumab Biosimilar) 抗体
Research Grade
适用: 人
ELISA
宿主: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- 抗原
- MS4A1 (Ocrelizumab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
- 宿主
-
Mammalian Cells
- Expression System
- Mammalian cells
- 克隆类型
- 单克隆
- 应用范围
- ELISA
- 原理
- Ocrelizumab Biosimilar - Anti-MS4A1, CD20 mAb
- 产品特性
- Antibody Type: IgG1-nd
- 纯化方法
- Recombinant antibody expressed in mammalien cells and purified.
- 质量等级
- Research Grade
- 亚型
- IgG1
-
- 限制
- 仅限研究用
-
- 缓冲液
- PBS pH 7.5
- 储存条件
- -80 °C
- 储存方法
- store at -80°C
-
- 抗原
- MS4A1 (Ocrelizumab Biosimilar)
- 物质类
- Biosimilar
- 背景
-
2H7
Ocrelizumab is a CD20-directed cytolytic antibody, which is suitable for the treatment of patients with relapsed or primary progressive multiple sclerosis. It is a second-generation recombinant humanized monoclonal antibody of isotype IgG1 that can selectively target B lymphocytes expressing CD20 antigen. Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system, which can cause neurological dysfunction. Most patients with MS experience recurrent episodes with functional deterioration, followed by recovery or remission. - CAS-编号
- 637334-45-3
-
You are here:
